All In MedTech

Device Trial Radar · NCT01701284

Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety

A Randomized Open-Label Pilot Trial To Evaluate The Safety And Efficacy Of Repetitive Transcranial Magnetic Stimulation In Cancer Patients With Depression And Anxiety

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Dec 2012

Primary completion

May 2023

Study completion May 2023

Sponsor

Lead sponsor
Northwestern UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Neuronetics
First posted
Oct 5, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a leading cause of mortality and morbidity worldwide. In addition, cancer is associated with high rates of depression and anxiety among its sufferers, and cancer patients with depression usually have worse treatment outcomes and long-term survival. Surprisingly, many cancer patients with depression do not receive treatment for their depression, perhaps because treatments for cancer-related depression are usually adapted from those used in non-cancer populations and may not be suitable for cancer patients. Moreover, cancer patients with depression are more likely to have a long latency of anti-depressant drug action, negative drug-drug interactions with cancer chemotherapies and an increased susceptibility for systemic side effects. Repetitive transcranial magnetic stimulation (rTMS) is a new treatment modality for depression that affects the brain directly with no systemic side effects and poses no potential for drug-drug interactions. rTMS therapy was recently cleared by the FDA as an antidepressant treatment for treatment-resistant Major Depressive Disorder, and now is being evaluated for a wide array of additional psychiatric indications. This randomized, open label, two-arm, pilot study will investigate the safety, tolerability, feasibility and the efficacy of two forms of rTMS (i.e., left (fast) and right (slow) sided rTMS) in cancer-related depression. The study hypotheses are that rTMS will significantly reduce symptoms of depression and that right-sided slow rTMS will be more effective than left-sided fast rTMS for the treatment of severe anxiety.

Conditions

  • Cancer in Remission (Any Type or Stage)
  • Depression
  • Anxiety

Interventions

  • Repetitive Transcranial Magnetic Stimulation (rTMS)Device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Change in Depression Severity (HDRS-17) at Weeks 2, 4, and 6Time frame: Baseline (Week 0), Week 2, Week 4 and Week 6.
  2. Relative Change in Depression Severity (HDRS-17) at Weeks 2, 4, and 6Time frame: Baseline (Week 0), Week 2, Week 4 and Week 6
  3. Number of Participants With Treatment-Emergent Side Effects (UKU)Time frame: Baseline (Week 0), Week 2, Week 4, and Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwestern University

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.